Michal Koc1, Michaela Šiklová1,2, Veronika Šrámková1,2, Marek Štěpán1,3, Eva Krauzová1,3, Vladimír Štich1,2,3, Lenka Rossmeislová1,2. 1. Department for Pathophysiology, Centre for Research on Nutrition, Metabolism and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia. 2. Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Prague, and Inserm, Toulouse, France. 3. Department of Internal Medicine, Third Faculty of Medicine, Charles University, and Kralovske Vinohrady University Hospital, Prague, Czechia.
Abstract
Aim: Development of type 2 diabetes (T2DM) is associated with disturbances in immune and metabolic status that may be reflected by an altered gene expression profile of peripheral blood mononuclear cells (PBMC). To reveal a potential family predisposition to these alterations, we investigated the regulation of gene expression profiles in circulating CD14+ and CD14- PBMC in fasting conditions and in response to oral glucose tolerance test (OGTT) in glucose tolerant first-degree relatives (FDR) of T2DM patients and in control subjects. Materials and Methods: This work is based on the clinical study LIMEX (NCT03155412). Non-obese 12 non-diabetic (FDR), and 12 control men without family history of diabetes matched for age and BMI underwent OGTT. Blood samples taken before and at the end of OGTT were used for isolation of circulating CD14+ and CD14- PBMC. In these cells, mRNA levels of 94 genes related to lipid and carbohydrate metabolism, immunity, and inflammation were assessed by qPCR. Results: Irrespectively of the group, the majority of analyzed genes had different mRNA expression in CD14+ PBMC compared to CD14- PBMC in the basal (fasting) condition. Seven genes (IRS1, TLR2, TNFα in CD14+ PBMC; ABCA1, ACOX1, ATGL, IL6 in CD14- PBMC) had different expression in control vs. FDR groups. OGTT regulated mRNA levels of nine genes selectively in CD14+ PBMC and of two genes (ABCA1, PFKL) selectively in CD14-PBMC. Differences in OGTT-induced response between FDR and controls were observed for EGR2, CCL2 in CD14+ PBMC and for ABCA1, ACOX1, DGAT2, MLCYD, and PTGS2 in CD14- PBMC. Conclusion: This study revealed a different impact of glucose challenge on gene expression in CD14+ when compared with CD14- PBMC fractions and suggested possible impact of family predisposition to T2DM on basal and OGTT-induced gene expression in these PBMC fractions. Future studies on these putative alterations of inflammation and lipid metabolism in fractionated PBMC in larger groups of subjects are warranted.
Aim: Development of type 2 diabetes (T2DM) is associated with disturbances in immune and metabolic status that may be reflected by an altered gene expression profile of peripheral blood mononuclear cells (PBMC). To reveal a potential family predisposition to these alterations, we investigated the regulation of gene expression profiles in circulating CD14+ and CD14- PBMC in fasting conditions and in response to oral glucose tolerance test (OGTT) in glucose tolerant first-degree relatives (FDR) of T2DM patients and in control subjects. Materials and Methods: This work is based on the clinical study LIMEX (NCT03155412). Non-obese 12 non-diabetic (FDR), and 12 control men without family history of diabetes matched for age and BMI underwent OGTT. Blood samples taken before and at the end of OGTT were used for isolation of circulating CD14+ and CD14- PBMC. In these cells, mRNA levels of 94 genes related to lipid and carbohydrate metabolism, immunity, and inflammation were assessed by qPCR. Results: Irrespectively of the group, the majority of analyzed genes had different mRNA expression in CD14+ PBMC compared to CD14- PBMC in the basal (fasting) condition. Seven genes (IRS1, TLR2, TNFα in CD14+ PBMC; ABCA1, ACOX1, ATGL, IL6 in CD14- PBMC) had different expression in control vs. FDR groups. OGTT regulated mRNA levels of nine genes selectively in CD14+ PBMC and of two genes (ABCA1, PFKL) selectively in CD14-PBMC. Differences in OGTT-induced response between FDR and controls were observed for EGR2, CCL2 in CD14+ PBMC and for ABCA1, ACOX1, DGAT2, MLCYD, and PTGS2 in CD14- PBMC. Conclusion: This study revealed a different impact of glucose challenge on gene expression in CD14+ when compared with CD14- PBMC fractions and suggested possible impact of family predisposition to T2DM on basal and OGTT-induced gene expression in these PBMC fractions. Future studies on these putative alterations of inflammation and lipid metabolism in fractionated PBMC in larger groups of subjects are warranted.
Authors: Jeremy P Mauldin; Suseela Srinivasan; Anny Mulya; Abraham Gebre; John S Parks; Alan Daugherty; Catherine C Hedrick Journal: J Biol Chem Date: 2006-05-24 Impact factor: 5.157
Authors: Theresia M Schnurr; Hermina Jakupović; Germán D Carrasquilla; Lars Ängquist; Niels Grarup; Thorkild I A Sørensen; Anne Tjønneland; Kim Overvad; Oluf Pedersen; Torben Hansen; Tuomas O Kilpeläinen Journal: Diabetologia Date: 2020-04-15 Impact factor: 10.122
Authors: A S Lihn; T Østergard; B Nyholm; S B Pedersen; B Richelsen; O Schmitz Journal: Am J Physiol Endocrinol Metab Date: 2002-10-08 Impact factor: 4.310
Authors: Sara Violante; Lodewijk Ijlst; Heleen Te Brinke; Janet Koster; Isabel Tavares de Almeida; Ronald J A Wanders; Fátima V Ventura; Sander M Houten Journal: Biochim Biophys Acta Date: 2013-07-10
Authors: T Elgzyri; H Parikh; Y Zhou; M Dekker Nitert; T Rönn; Å B Segerström; C Ling; P W Franks; P Wollmer; K F Eriksson; L Groop; O Hansson Journal: J Clin Endocrinol Metab Date: 2012-04-30 Impact factor: 5.958
Authors: Jane Palsgaard; Charlotte Brøns; Martin Friedrichsen; Helena Dominguez; Maja Jensen; Heidi Storgaard; Camilla Spohr; Christian Torp-Pedersen; Rehannah Borup; Pierre De Meyts; Allan Vaag Journal: PLoS One Date: 2009-08-11 Impact factor: 3.240
Authors: Jesús Zacarías Villarreal-Pérez; Jesús Zacarías Villarreal-Martínez; Fernando Javier Lavalle-González; María Del Rosario Torres-Sepúlveda; Consuelo Ruiz-Herrera; Ricardo Martín Cerda-Flores; Erik Rubén Castillo-García; Irám Pablo Rodríguez-Sánchez; Laura Elia Martínez de Villarreal Journal: Diabetol Metab Syndr Date: 2014-11-27 Impact factor: 3.320